The tool for early detection of dementia
Neurosalience® is a tool for early detection of dementia from structural MRI and CT data capable of processing even low-resolution MRI data and CT scans.
Neurosalience® is a tool for early detection of dementia from structural MRI and CT data capable of processing even low-resolution MRI data and CT scans.
In the world due to population ageing it is predicted that the number of patients with dementia will rise to 75 million by 2030.
In UK average cost per patient is over 32 000 pounds a year. Current diagnostic pipeline allows only to start treatment and lifestyle changes once the symptoms have occurred.
75 million patients by 2030
Average cost = £32K per patient
Existing screening methods:
-Lack sensitivity
-Are not automated enough
-Detect existing symptoms
At Neurosalience we develop a tool for early detection of dementia from structural MRI scans. The tool is the first in the world to be capable of assessing risk of dementia even on low resolution MRI data and be extendable to be used on CT data.
Early detection of the risk of dementia allows to reduce long-term patient-related care costs and improve the quality of life of the people as there are scientifically proven lifestyle changes enabling to decelerate the course of disease.
We use interpretable machine learning algorithms to assess brain ageing.
view our technology
We are open to collaboration and partnership with hospitals, MedTech and pharma companies. Contact us to arrange a demo of our product!
